Previous 10 | Next 10 |
Renowned Cardiothoracic Surgeon to Join Experienced Medical Device Technology Leadership Team to Bring nsPFA to Cardiac Surgery Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Fiel...
Collaboration with CardioNXT provides navigation and mapping system integration with Pulse Biosciences’ nsPFA circumferential catheter to support first-in-human treatments Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveragi...
Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced its nsPFA technology will be featured in a present...
First prospective clinical feasibility study suggests nsPFA may be a safe and effective method for treating benign thyroid tumors or nodules Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecon...
2023-08-29 12:59:54 ET Gainers: iCoreConnect ( ICCT ) +255% . Axcella Health ( AXLA ) +254% . Tivic Health Systems ( TIVC ) +61% . Taysha Gene Therapies ( TSHA ) +35% . Big Lots ( BIG ) +32% . EBET ( EBET ) +32% . ...
Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today provided additional clarification regarding the details of t...
2023-08-10 21:04:11 ET Pulse Biosciences Inc. (PLSE) Q2 2023 Results Conference Call August 10, 2023 4:30 PM ET Company Participants Philip Taylor - IR Kevin Danahy - Chief Executive Officer Darrin Uecker - CTO & Director Mitchell Levinson - Chief Strateg...
2023-08-10 16:28:18 ET Pulse Biosciences press release ( NASDAQ: PLSE ): Q2 GAAP EPS of -$0.22 beats by $0.02 . Cash and cash equivalents totaled $58.7 million as of June 30, 2023, compared to $14.8 million as of June 30, 2022 and $54.1 million as of March 31, 2023. ...
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced financial results for the second quarter ended June 30, 2023. Business Up...
2023-08-01 01:59:28 ET Summary After covering second-quarter corporate insider activity among mid-cap and large-caps, today's article will cover on the most interesting insider purchases for small-cap companies. Corporate insiders at American Assets Trust, National Vision, Skillz,...
News, Short Squeeze, Breakout and More Instantly...
Pulse Biosciences Inc Company Name:
PLSE Stock Symbol:
NASDAQ Market:
Pulse Biosciences Inc Website:
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, announced today the closing of its rights offering and the fi...
2024-06-25 21:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-15 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...